Australia Women'S Health Market Size & Outlook, 2026-2033
Global Market
Related Markets
Australia women's health market highlights
- The Australia women's health market generated a revenue of USD 1,137.0 million in 2025 and is expected to reach USD 1,907.0 million by 2033.
- The Australia market is expected to grow at a CAGR of 6.4% from 2026 to 2033.
- In terms of segment, contraceptives was the largest revenue generating application in 2025.
- Menopause is the most lucrative application segment registering the fastest growth during the forecast period.
Women's health market data book summary
| Market revenue in 2025 | USD 1,137.0 million |
| Market revenue in 2033 | USD 1,907.0 million |
| Growth rate | 6.4% (CAGR from 2026 to 2033) |
| Largest segment | Contraceptives |
| Fastest growing segment | Menopause |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, Australia accounted for 2.1% of the global women's health market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, Japan women's health market is projected to lead the regional market in terms of revenue in 2033.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 4,721.0 million by 2033.
According to the Fertility Society of Australia and New Zealand, every sixth couple has trouble becoming pregnant. Problems with fertility can be brought on by illnesses and other conditions. Overall, female reproductive difficulties account for one-third of infertility cases.
Such factors are expected to boost market growth. Moreover, players in the country are adopting various strategies to expand their market presence and meet consumer demand. For instance, in July 2022, Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA announced the availability of NEXTSTELLIS, an oral contraceptive with a novel estrogen in Australia.
Similarly, in October 2021, Slinda, a contraceptive pill manufactured by Exeltis, became available in Australia. Moreover, favorable initiatives undertaken by government bodies to consume contraceptive pills are expected to drive the market.
No credit card required*
Publish Date: Feb 11, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Women's Health Market Scope
Women's Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Ferring | View profile | 5001-10000 | Saint-prex, Vaud, Switzerland, Europe | www.ferring.com |
| Agile Therapeutics Inc | View profile | 19 | 500 College Road East, Suite 310, Princeton, NJ, United States, 08540 | www.agiletherapeutics.com |
| Blairex Laboratories | View profile | 101-250 | Columbus, Indiana, United States, North America | www.blairex.com |
| Apothecus | View profile | 11-50 | Hicksville, New York, United States, North America | apothecus.com |
Australia Women's Health Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Women's Health Market Outlook will help companies and investors design strategic landscapes.
Contraceptives was the largest segment with a revenue share of 30.17% in 2025.
Horizon Databook has segmented the Australia women's health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2021 to 2033.
According to the Fertility Society of Australia and New Zealand, every sixth couple has trouble becoming pregnant. Problems with fertility can be brought on by illnesses and other conditions. Overall, female reproductive difficulties account for one-third of infertility cases.
Such factors are expected to boost market growth. Moreover, players in the country are adopting various strategies to expand their market presence and meet consumer demand. For instance, in July 2022, Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA announced the availability of NEXTSTELLIS, an oral contraceptive with a novel estrogen in Australia.
Similarly, in October 2021, Slinda, a contraceptive pill manufactured by Exeltis, became available in Australia. Moreover, favorable initiatives undertaken by government bodies to consume contraceptive pills are expected to drive the market.
- Australia Women'S Health Market Application Outlook (Revenue, USD Million , 2021-2033)
- Hormonal Infertility
- Contraceptives
- Postmenopausal Osteoporosis
- Endometriosis & Uterine Fibroids
- Menopause
- Polycystic Ovary Syndrome (PCOS)
- Australia Women'S Health Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Hormonal Therapies
- Bone Health Agents
- Fertility Agents
- GnRH Modulators
- Pain and Symptom Management
- Metabolic Agents
- Others Drug Class
- Australia Women'S Health Market Age Outlook (Revenue, USD Million , 2021-2033)
- 50 years and above
- Others Age
Reasons to subscribe to Women's Health Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Women's Health Market Outlook databook
- Our clientele includes a mix of Women's Health Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia Women's Health Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Australia Women's Health Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Australia Women'S Health Market, 2021-2033 (US$M)
Australia women's health market statistics, by application, 2021-2033 (US$M)
